EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAFV600E

Samar A El-Kalyoubi iD, Hesham A M Gomaa iD, Elshimaa M N Abdelhafez iD, Mohamed Ramadan iD, Fatimah Agili, Bahaa G M Youssif

Pharmaceuticals · 08.05.2023 · 16 (5) · 716

DOI: 10.3390/ph16050716 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 08.05.2023. Verfasst von Samar A El-Kalyoubi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Port Said University, Port Said 42511, Egypt. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The investigation of novel EGFR and BRAFV600E dual inhibitors is intended to serve as targeted cancer treatment. Two sets of purine/pteridine-based derivatives were designed and synthesized as EGFR/BRAFV600E dual inhibitors. The majority of the compounds exhibited promising antiproliferative activity on the cancer cell lines tested. Compounds 5a, 5e, and 7e of purine-based and pteridine-based scaffolds were identified as the most potent hits in anti-proliferative screening, with GI50 values of 38 nM, 46 nM, and 44 nM, respectively. Compounds 5a, 5e, and 7e demonstrated promising EGFR inhibitory activity, with IC50 values of 87 nM, 98 nM, and 92 nM, respectively, when compared to erlotinib’s IC50 value of 80 nM. According to the results of the BRAFV600E inhibitory assay, BRAFV600E may not be a viable target for this class of organic compounds. Finally, molecular docking studies were carried out at the EGFR and BRAFV600E active sites to suggest possible binding modes.

Schlagwörter

Stichwörter der Autor:innen

BRAFEGFRanti-proliferativecancerdockingpteridinepurine

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Port Said University, Port Said 42511, Egypt.
  • Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka 72341, Aljouf, Saudi Arabia.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 11651, Egypt.
  • Chemistry Department, Faculty of Science (Female Section), Jazan University, Jazan 82621, Jazan, Saudi Arabia.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.

ORCID-Profile: Samar A El-Kalyoubi, Hesham A M Gomaa, Elshimaa M N Abdelhafez, Mohamed Ramadan

Zitieren

APA

El-Kalyoubi, S. A., Gomaa, H. A. M., Abdelhafez, E. M. N., Ramadan, M., Agili, F., & Youssif, B. G. M. (2023). Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAFV600E. Pharmaceuticals, 16(5), 716. https://doi.org/10.3390/ph16050716

Vancouver

El-Kalyoubi SA, Gomaa HAM, Abdelhafez EMN, Ramadan M, Agili F, Youssif BGM. Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAFV600E. Pharmaceuticals. 2023;16(5):716. doi:10.3390/ph16050716

BibTeX
@article{ElKalyoubi2023,
  author = {El-Kalyoubi, Samar A and Gomaa, Hesham A M and Abdelhafez, Elshimaa M N and Ramadan, Mohamed and Agili, Fatimah and Youssif, Bahaa G M},
  title = {Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAFV600E},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {5},
  pages = {716},
  doi = {10.3390/ph16050716}
}
Kostenlos starten →